Centrally acting imidazoline I1-receptor agonists:Do they have a place in the management of hypertension?

American Journal of Cardiovascular Drugs

Volumn 1, Issue 5, 2001, Pages 321-326

  Van Zwieten, P A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DRUG RECEPTOR; IMIDAZOLE DERIVATIVE; IMIDAZOLINE I1 RECEPTORS; MOXONIDINE; OXAZOLE DERIVATIVE; RILMENIDINE;

ANIMAL; DRUG POTENTIATION; HUMAN; HYPERTENSION; REVIEW;

ANIMALS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; IMIDAZOLES; OXAZOLES; RECEPTORS, DRUG;

EID: 2442622303     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/00129784-200101050-00002     Document Type: Review

References (17)

1. Van Zwieten PA, Chalmers JP. Different types of centrally acting antihypertensives and their targets in the central nervous system. Cardiovasc Drugs Ther 1994; 8: 787-99
2. Hieble JP, Ruffolo RR. Imidazoline receptors: historical perspective. Fundam Clin Pharmacol 1992; 6 Suppl. 1: S7-13
3. Feldman J, Tibirica E, Bricca G, et al. Evidence for the involvement of imidazoline receptors in the central hypotensive effect of rilmenidine in the rabbit. Br J Pharmacol 1990; 100: 600-4
4. Bousquet P, Reid JL. Imidazoline receptors in a comprehensive approach to hypertension. J Cardiovasc Pharmacol 1995; 26 Suppl. 2: S1-67
5. Van Zwieten PA. Central imidazoline (I1)-receptors as targets of centrally acting antihypertensives: moxonidine and rilme-nidine. J Hypertens 1997; 15: 117-25
6. Prichard BN, Graham BR, Owens CW. Moxonidine, a new anti-adrenergic antihypertensive. J Hypertens 1999; 17 Suppl. 3: 541-54
7. Trimarco B, Morisco C, Sarno D, et al. Rilmenidine in patients with left ventricular hypertrophy: beyond the reduction of left ventricular mass. J Cardiovasc Pharmacol 1995: 26 Suppl. 2: S29-33
8. Kaan EC, Br?ckner R, Frohly P, et al. Effects of agmatine and moxonidine on glucose metabolism. Cardiovasc Risk Fact 1995; 5: 19-27
9. Rupp H, Maisch B, Brilla C. Drug withdrawal and rebound hypertension. Differential action of the central antihyper-tensive drugs moxonidine and clonidine. Cardiovasc Drugs Ther 1996; 10: 251-62
10. Reid JL. Rilmenidine: a clinical overview. Am J Hypertens 2000; 13: S106-11
11. Piletz JE, Ivanov TR, Sharp JD, et al. Imidazoline receptor antisera selected (IRAS) DNA: cloning and characterization. DNA Cell Biol 2000; 6: 319-29
12. Seperovic D, Kosta M, Ernsberger P. Coupling of I1-imidazoline receptors to diacylglyceride accumulation in PC 12 rat phaeochromocytoma cells. Mol Pharmacol 1996; 49: 668-75
13. Bousquet P. I1-receptors, cardiovascular function and metabolism. J Hypertens press
14. Mayorov DN, Burke SL, Head GA. Relative importance of rostral ventrolateral medulla in sympathoinhibitory action of rilmenidine in conscious and anesthetized rabbits. J Cardiovasc Pharmacol 2001; 37: 252-61
15. Manolis AJ, Olympios C, Sifaki M, et al. Suppressing sympathetic activation in congestive heart failure. Hypertension 1995; 26: 719-24
16. Krentz AJ, Evans AJ. Selective imidazoline receptor agonist for metabolic syndrome. Lancet 1998; 351: 152-4
17. Haenni A, Lithell H. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens 1999; 17 Suppl. 4: S29-36